FORMYCON AG chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 2.29
Dividend & YieldN/A€ (N/A)
Beta 1.05
Market capitalization 1.35B
Operating cash flow -16.85M
ESG Scores unknown

Company description

Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -205.9k -335k 1.95M 550k
Total Cashflows From Investing Activities -17.03M -5.71M -648k -4.24M
Net Borrowings
Total Cash From Financing Activities 564.7k 17.24M 25.64M 1.35M
Change To Operating Activities 786.9k -704k 269k 2.15M
Issuance Of Stock 597.7k 17.26M 25.75M 1.51M
Net Income 7.1M -2.29M -5.93M -13.48M
Change In Cash -3.17M 10.05M 19.89M -17.07M
Effect Of Exchange Rate
Total Cash From Operating Activities 13.3M -1.48M -5.1M -14.18M
Depreciation 904.3k 912k 915k 943k
Change To Account Receivables
Other Cashflows From Financing Activities -33k -28k -106k -166k
Change To Netincome 61.98k 32.29k 171k 339k
Capital Expenditures -951k -923k -558k -704k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development
Income Before Tax 7.1M -2.3M -5.84M -13.51M
Net Income 7.1M -2.29M -5.93M -13.48M
Selling General Administrative 7.93M 9.09M 10.03M 13M
Gross Profit 18.73M 10.97M 8.76M 1.01M
Ebit 7.12M -2.27M -5.74M -13.31M
Operating Income 7.12M -2.27M -5.74M -13.31M
Interest Expense -32.96k -28.25k -106k -166k
Income Tax Expense -8.55k 90k -30k
Total Revenue 42.99M 33.16M 34.23M 36.97M
Cost Of Revenue 24.27M 22.19M 25.47M 35.96M
Total Other Income ExpenseNet -20.88k -28.2k -94k -200k
Net Income From Continuing Ops 7.1M -2.29M -5.93M -13.48M
Net Income Applicable To Common Shares 7.1M -2.29M -5.93M -13.48M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 6.38M 5.34M 7.56M 10.26M
Total Stockholder Equity 33.24M 48.21M 68.03M 56.07M
Other Current Liabilities 901.1k 1.1M 1.01M 3.28M
Total Assets 39.62M 53.56M 75.6M 66.33M
Common Stock 9.42M 10M 11M 11.06M
Other Current Assets 53.96k 379.22k 130k 3.21M
Retained Earnings -11.73M -14.03M -19.95M -33.43M
Treasury Stock 35.55M 52.24M 76.99M 78.44M
Cash 7.34M 22.12M 42.01M 25.03M
Total Current Liabilities 3.85M 4.62M 7.03M 9.89M
Other Stockholder Equity 35.55M 52.24M 76.99M 78.44M
Property, Plant, and Equipment 3.47M 3.7M 3.5M 3.28M
Total Current Assets 18.75M 28.06M 50.51M 37.99M
Net Tangible Assets 32.47M 47.58M 67.54M 55.36M
Net Receivables 5.17M 4.92M 6.89M 7.75M
Accounts Payable 2.73M 2.21M 4.48M 4.73M


Insider Transactions

Here are the insider transactions of stock shares related to FORMYCON AG:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to FORMYCON AG. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on FORMYCON AG

Here is the result of two systematic investment strategies applied to FORMYCON AG. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on FORMYCON AG

The following chart shows the equity curve of the two systematic investment strategies applied to FORMYCON AG:

FORMYCON AG automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 51.64% on the backtest period.

Performance at glance

Performance

51.64 %

Latent gain

789.85 €

Invested capital

1529.6 €

Annualized return

12.53 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on FORMYCON AG

This is the result of two momentum investment strategies applied to FORMYCON AG. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on FORMYCON AG

The following chart shows all the entries opened by the momentum investment system on FORMYCON AG:

FORMYCON AG momentum entries
  • The first momentum investment strategy would give 45.68% of return on FORMYCON AG. That represents 2491.25€ of latent gain with 5454.1€ of employed capital.
  • The second momentum investment strategy would give 51.38% of return on FORMYCON AG. That represents 1155.8€ of latent gain with 2249.35€ of employed capital.
Performance at glance (1Q Momentum)

Performance

45.68 %

Latent gain

2491.25 €

Invested capital

5454.1 €

Annualized return

45.85 %
Performance at glance (2Q Momentum)

Performance

51.38 %

Latent gain

1155.8 €

Invested capital

2249.35 €

Annualized return

14.12 %

Momentum equity curve on FORMYCON AG

The following chart shows the equity curve of the two momentum strategies applied to FORMYCON AG:

FORMYCON AG momentum equity

Note: the dividends potentially given by FORMYCON AG are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on FORMYCON AG

The following chart shows the employed capital evolution of the two momentum strategies on FORMYCON AG since the beginning:

FORMYCON AG

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250€, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000€.


Buy the dip strategy result on FORMYCON AG

Buy the dip entry openings on FORMYCON AG

FORMYCON AG

The performance achieved by the robo-advisor on FORMYCON AG is 97.2%. That represents 486.5$ of latent gain with 500.5€ of employed capital. The following chart shows FORMYCON AG stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of FORMYCON AG, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

97.2 %

Latent gain

486.5 €

Invested capital

500.5 €

Annualized return

45.85 %

Equity curve of the strategy applied to FORMYCON AG

The following chart shows the result of the investment strategy applied to FORMYCON AG:

FORMYCON AG

Note: the dividends potentially given by FORMYCON AG are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on FORMYCON AG

The following chart shows the employed capital evolution since the beginning of the investment strategy on FORMYCON AG:

FORMYCON AG

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on FORMYCON AG

In this section, I will compare the three previous investment strategies applied to FORMYCON AG.

Equity curve comparison on FORMYCON AG

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

FORMYCON AG investment strategy comparison

Employed capital comparison on FORMYCON AG

FORMYCON AG investment comparison

Performance comparison on FORMYCON AG

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 51.64% 789.85€ 1529.6€ 12.53%
Momentum 1 quarter 45.68% 2491.25€ 5454.1€ 11.77%
Momentum 2 quarters 51.38% 1155.8€ 2249.35€ 14.12%
Non-directional 97.2% 486.5€ 500.5€ 45.85%
Annualized return comparison

Automatic investment

12.53 %

Momentum 1Q

14.12 %

Momentum 2Q

14.12 %

Non-directional

45.85 %

Correlated stocks

Here are the most positively and negatively correlated stocks with FORMYCON AG:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between FORMYCON AG and the other stocks. There may be false positives or some missing correlated stocks. If the price of FORMYCON AG does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name FORMYCON AG
Country Germany
City Planegg
Address Fraunhoferstrasse 15
Phone 49 89 864 667 100
Website www.formycon.com
FullTime employees 146
Industry Biotechnology
Sector Healthcare
Exchange XETRA
Ticker FYB.XETRA
Market www.xetra.com

FORMYCON AG ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown